Weight loss injections in the belly: what to expect and how they work

Why is the abdomen used as an injection site?

Both Mounjaro and Wegovy are subcutaneous injections, meaning the medicine goes into the fatty tissue just beneath the skin rather than into muscle. The belly has a reliable layer of subcutaneous fat for most adults, which makes absorption predictable and the injection itself relatively comfortable. That said, the outer thigh and upper arm are equally valid sites, and you can find more detail on the options if you read through how weight-loss injections work in practice.

Rotating your site matters. Using exactly the same spot every week can cause a small lump of fatty tissue to build up (lipohypertrophy), which affects how well the medicine absorbs. Within the abdomen, aim at least two to three centimetres from the navel and move around the area each time. The Patient Information Leaflet included with your pen describes this in full, and your prescriber will go through it with you.

The needle on a pre-filled pen is very short, designed for subcutaneous tissue, not deep tissue. Pinching a small fold of skin at the site, pressing the pen flush, and holding it still for the recommended count is the standard technique. Most people find the sensation much milder than they expect, and if you want a broader overview of what to expect from weight loss injections before you begin, that page is a good starting point. Cleaning the area first with an alcohol swab is straightforward and worth building into the routine.

Does injecting into the belly actually target belly fat?

This is probably the question our prescribers hear most often. The short answer: no, injecting into the abdomen does not preferentially reduce fat from that area. The medicine enters the bloodstream through the subcutaneous tissue and acts on receptors throughout the body (particularly in the brain and gut) to reduce appetite and slow gastric emptying. Where the body loses fat is determined by your biology, not the injection site.

GLP-1 medicines like semaglutide and dual-agonist medicines like tirzepatide work on appetite signalling, not local fat deposits. The evidence on weight-loss injections and abdominal fat is more nuanced than the marketing around "belly injections" often suggests, overall weight loss tends to reduce visceral fat alongside subcutaneous fat, which is clinically meaningful for cardiovascular and metabolic health, but it is not spot reduction.

In the SURMOUNT-1 trial, adults taking tirzepatide 15mg lost an average of around 20–21% of body weight over 72 weeks, as published in the New England Journal of Medicine. That kind of overall reduction does significantly affect the midsection, but as part of systemic change rather than targeted action at the injection site.

Who can be prescribed this treatment, and what does the process look like?

UK licensing for Mounjaro and Wegovy covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses the full picture, not just the number on the scales, medical history, current medicines, and any contraindications all feed into the decision.

The eligibility criteria for weight-loss injections are set by the medicine's licence, and a prescriber at a regulated pharmacy applies them individually. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it is submitted. There is no algorithm making that call.

Once approved, your pen arrives via DPD the next working day in plain, unbranded packaging, the tracking notification comes to your phone so you know exactly when to expect it. The pen itself is pre-filled and pre-set; no drawing up of medicine, no complicated assembly. The Mounjaro KwikPen locks after use and should be disposed of in a proper sharps container, which is worth arranging before your first dose.

What side effects should you know about before starting?

The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. These tend to be most noticeable in the first days after a new dose and often settle as the body adjusts. Starting at a low dose (the first Mounjaro pen is 2.5mg, not the maintenance level) is specifically designed to give your system time to adapt before any increase. The NHS tirzepatide page has a full side-effect profile worth reading before you begin.

More serious effects are less common but need prompt attention. Severe, persistent stomach pain that spreads toward the back can signal pancreatitis and requires urgent medical assessment, the MHRA highlighted this in a Drug Safety Update for GLP-1 medicines. Signs of a significant allergic reaction, gallbladder symptoms, or unusual mood changes should also be discussed with a healthcare professional without delay. Yellow Card reporting for any suspected side effect is available at yellowcard.mhra.gov.uk.

Women taking oral contraceptives should discuss this with their prescriber before starting tirzepatide specifically, as absorption of the pill may be temporarily reduced at the start of treatment and after each dose increase, an additional non-oral contraceptive method is advised during those windows. If you have questions about managing other medicines alongside your weight loss injection treatment, the FAQs cover several of the most common ones, and the aftercare team at nume is available seven days a week.

If you're ready to find out whether you're a suitable candidate, you can start your free consultation, a prescriber reviews your answers the same day.